Drug Combination Details
| General Information of the Combination (ID: C87955) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Everolimus Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | QGP-1 | CVCL_3143 | Pancreatic somatostatinoma | Homo sapiens | ||
| NCI-H727 | CVCL_1584 | Lung carcinoid tumor | Homo sapiens | |||
| Experimental
Result(s) |
Metformin and everolimus in combination are more effective than monotherapy in inhibiting pancreatic NET (PAN-NET) cell proliferation, whereas no additive effects were observed on pulmonary neuroendocrine tumor (PNT) cell proliferation. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCC1428 | CVCL_1252 | Breast adenocarcinoma | Homo sapiens | ||
| MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | |||
| BT-549 | CVCL_1092 | Invasive breast carcinoma | Homo sapiens | |||
| In-vivo Model | HCC1428 cells (1.0*106) were injected subcutaneously into the abdominal mammary fat pads of female BALB/c-nu mice. | |||||
| Experimental
Result(s) |
Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. | |||||
